Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, considers combination pembrolizumab and olaparib and what primary endpoints should look like in these first line metastatic castration-resistant prostate cancer (mCRPC) trials

Tags: ASCO GU Conference CoverageProstate

Published: 22 February 2019

Recent Videos

video

Parameswaran Hari, MD, MRCP, on novel combination treatment options & sequencing strategies in MM

Dr. Hari, Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, explains how novel combination treatment options and sequencing strategies are ...

video

Parameswaran Hari, MD, MRCP, considers the role of stem cell transplantation in myeloma

Dr. Hari, Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, elaborates on the role of stem cell transplantation in the ...

video

Parameswaran Hari, MD, MRCP, tells us about the design & outcomes of the STORM and Mammoth studies

Dr. Hari, Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, tells us about the design and outcomes of the STORM ...

video

Deepu Madduri, MD, explains how JNJ-4528 differs from other CAR-T products

Dr. Madduri, Assistant Professor, Medicine, Hematology and Medical Oncology, The Mount Sinai Hospital, explains how JNJ-4528 differs from other CAR-T ...

video

Leslie Popplewell, MD, summarizes the role of checkpoint inhibitors in the treatment of lymphomas

Dr. Popplewell, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope, summarizes the ...

video

Catherine Smith, MD, discusses prognostic factors and outcomes in acute myeloid leukemia

Dr. Smith, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, UCSF, discusses the prognostic factors in acute myeloid leukemia (AML) ...

video

Leslie Popplewell, MD, on the role of CAR-T cell therapy in aggressive B-cell lymphomas

Dr. Popplewell, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope, shares her ...

video

Catherine Smith, MD, offers her overall impression on the changing FLT3 inhibition landscape in AML

Dr. Smith, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, UCSF, offers her overall impression on the changing FLT3 inhibition ...

video

Leslie Popplewell, MD, considers the use of CAR-T cell therapies in aggressive B-cell lymphomas

Dr. Popplewell, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope, discusses clinical ...

video

Catherine Smith, MD, on whether all acute myeloid leukemia patients should be tested for FLT3

Dr. Smith, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, UCSF, on whether all acute myeloid leukemia (AML) patients should ...

Related Videos

video-image

Parameswaran Hari, MD, MRCP, tells us about the design & outcomes of the STORM and Mammoth studies

video-image

Parameswaran Hari, MD, MRCP, considers the role of stem cell transplantation in myeloma

video-image

Parameswaran Hari, MD, MRCP, on novel combination treatment options & sequencing strategies in MM

video-image

Catherine Smith, MD, offers her overall impression on the changing FLT3 inhibition landscape in AML

video-image

Leslie Popplewell, MD, on the role of CAR-T cell therapy in aggressive B-cell lymphomas

video-image

Catherine Smith, MD, discusses prognostic factors and outcomes in acute myeloid leukemia

video-image

Leslie Popplewell, MD, summarizes the role of checkpoint inhibitors in the treatment of lymphomas

video-image

Deepu Madduri, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

Leslie Popplewell, MD, offers opinion on the next frontier in the development of CAR-T treatment

video-image

Catherine Smith, MD, tells us about the outcomes of the Phase 3 ADMIRAL trial presented at ASH 2019

video-image

Deepu Madduri, MD, on how CAR-T cell therapy plays a role in the management of multiple myeloma

video-image

Leslie Popplewell, MD, considers whether there is sufficient evidence supporting bridging therapy

video-image

Catherine Smith, MD, on whether all acute myeloid leukemia patients should be tested for FLT3

video-image

Leslie Popplewell, MD, considers the use of CAR-T cell therapies in aggressive B-cell lymphomas

video-image

Deepu Madduri, MD, elaborates on the outcomes of the CARTITUDE-1 study

video-image

Christian Rolfo, MD, PhD, MBA, on the role of liquid biopsy in the treatment of lung cancer

video-image

Nader Sanai, MD, offers perspective on the challenges in treating glioblastoma

video-image

Brian Van Tine, MD, shares some of the top studies in sarcoma presented at ESMO 2019

video-image

Dennis J. Slamon, MD, PhD, discusses implications from the MONALEESA-3 trial

video-image

Arndt Vogel, MD, elaborates on the results of the CheckMate-459 study in HCC